{"schema_version":"secwatch.filing_event.v1","accession":"0001826667-25-000115","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.171025+00:00","generated_at":"2026-05-17T14:48:46.986258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M","bullets":["Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.","Operating loss improved to $7.3M from $8.2M; net loss $9.0M ($0.27 diluted EPS loss).","Reaffirmed FY2025 revenue growth at least 50%; cash $26.5M, runway to positive adj. EBITDA H1 2026.","Launched TriNav FLX for tortuous vessels; early sales exceeded internal projections.","Simplified capital structure via exchange of Series A Preferred stock completed post-quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001826667-25-000115","json":"https://secwatch.observer/filing/0001826667-25-000115.json","markdown":"https://secwatch.observer/filing/0001826667-25-000115.md","text":"https://secwatch.observer/filing/0001826667-25-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/0001826667-25-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/tlsi-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:48:46.986258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}